To the extent that bone cancer pain has a neuropathic component, Ghilardi et al. [47] have demonstrated that daily administration of JNJ-17203212, a prototype TRPV1 antagonist, attenuated spontaneous and palpitation-induced flinching by approximately 50% compared to vehicle treated mice. Here, TRPV1 is linked to bone cancer.